AMS, the United Kingdom-based developer of products for tissue repair, reported preliminary full-year results for 2025 showing revenue expansion of 29% compared with the prior year. Management attributed the increase to a combination of organic growth and the contribution from acquisitions completed in the period.
On a profitability basis, adjusted EBITDA rose 24% in 2025. Adjusted diluted earnings per share increased 12% year-over-year. The company reported adjusted earnings per share of
Adjusted pretax profit for the year reached
The company recorded adjusted pretax profit of
The board proposed a 10% rise in the full-year dividend, reflecting management's stated confidence in the company's outlook.
Looking ahead to 2026, AMS issued guidance that includes revenue of
Management expects 2026 revenue of
Specifically, the company expects 2026 revenue of
Alongside revenue guidance, AMS expects adjusted EBITDA of
The company highlighted that the full-year contribution from its Peters Surgical and Syntacoll acquisitions was a key driver of revenue growth and broadened its product range. The Surgical division was singled out for a particularly strong performance, with growth across adhesives, biosurgical devices, and sutures and meaningful gains reported in the US and Asia-Pacific markets.
Woundcare, which underwent a restructuring, returned to growth during the year. Management cited new supply agreements and a strategic emphasis on higher-margin products as supporting factors for the recovery in that business.
AMS also noted an expectation of multiple product approvals from 2026 onwards, covering adhesives, sutures, and collagen technologies. The company expects these approvals to be part of its forward product pipeline but did not quantify timing beyond the general 2026 reference.
Financial highlights at a glance
- Revenue growth 2025: 29%
- Adjusted EBITDA increase: 24%
- Adjusted diluted EPS increase: 12%
- Adjusted EPS:
- Adjusted pretax profit:
- Proposed dividend increase: 10%
These results and the guidance indicate that AMS expects the momentum of its Surgical division and the contribution from recent acquisitions to continue influencing near-term performance. The return to growth in Woundcare and the pipeline of prospective product approvals are presented as supporting elements of the company's outlook for 2026.